Seres Therapeutics (NASDAQ:MCRB) Upgraded at Wall Street Zen

Seres Therapeutics (NASDAQ:MCRB) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Seres Therapeutics in a research report on Friday, March 13th. Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Seres Therapeutics Stock Down 3.2%

Shares of Seres Therapeutics stock opened at $6.63 on Friday. The stock’s fifty day moving average is $8.08 and its two-hundred day moving average is $11.82. The company has a market capitalization of $64.18 million, a PE ratio of -1.28 and a beta of 0.13. Seres Therapeutics has a 52 week low of $6.32 and a 52 week high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million.

Hedge Funds Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Seres Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after buying an additional 1,160 shares in the last quarter. Invesco Ltd. grew its position in shares of Seres Therapeutics by 37.5% during the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after buying an additional 3,918 shares in the last quarter. State Street Corp grew its position in shares of Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after buying an additional 4,170 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Seres Therapeutics by 4.8% during the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.